<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the safety and efficacy of treatment with insulin alone, insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi>, or insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi> in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 88 type 2 diabetic subjects using insulin monotherapy (baseline HbA(lc) 8.7%) were randomly assigned to insulin alone (n = 31), insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> (n = 27), or insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi> (n = 30) for 4 months </plain></SENT>
<SENT sid="2" pm="."><plain>The insulin dose was increased only in the insulin group </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> was titrated to a maximum dose of 2,000 mg and <z:chebi fb="0" ids="9753">troglitazone</z:chebi> to 600 mg </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: HbA(lc) levels decreased in <z:hpo ids='HP_0000001'>all</z:hpo> groups, the lowest level occurring in the insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi> group (insulin alone to 7.0%, insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> to 7.1%, and insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi> to 6.4%, P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>The dose of <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">insulin increased</z:e> by 55 units/day in the insulin alone group (P &lt; 0.0001) and decreased by 1.4 units/day in the insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> group and 12.8 units/day in the insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi> group (insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> versus insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi>, P = 0.004) </plain></SENT>
<SENT sid="6" pm="."><plain>Body weight increased by 0.5 kg in the insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> group, whereas the other two groups gained 4.4 kg (P &lt; 0.0001 vs. baseline) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="17855">Triglyceride</z:chebi> and <z:chebi fb="0" ids="47776">VLDL triglyceride</z:chebi> levels significantly improved only in the insulin plus <z:chebi fb="0" ids="9753">troglitazone</z:chebi> group </plain></SENT>
<SENT sid="8" pm="."><plain>Subjects taking <z:chebi fb="0" ids="6801">metformin</z:chebi> experienced significantly more gastrointestinal side effects and less <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Aggressive insulin therapy significantly improved glycemic control in type 2 diabetic subjects to levels comparable with those achieved by adding <z:chebi fb="0" ids="6801">metformin</z:chebi> to insulin therapy </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="9753">Troglitazone</z:chebi> was the most effective in lowering HbA(lc), total daily insulin dose, and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels </plain></SENT>
<SENT sid="11" pm="."><plain>However, treatment with insulin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> was advantageous in avoiding <z:mp ids='MP_0005456'>weight gain</z:mp> and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
</text></document>